Version history

{
  "description": "The clinical trialist identified this as a 'fatal clinical flaw' - no validated biomarkers exist to measure restored compartmentalization in patients. Without measurable endpoints, therapeutic approaches targeting subcellular localization cannot advance to clinical trials.\n\nSource: Debate session sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47 (Analysis: SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47)",
  "domain": "neuroscience",
  "status": "partially_addressed",
  "priority_score": 0.9,
  "source": "debate:sess_SDA-2026-04-08-gap-pubmed-20260406-062222-cc3bcb47",
  "resolution_criteria": "Resolution requires: (1) validated biomarker panel (≥3 markers) measured in CSF or blood from AD patients (n≥100) that correlates with compartmentalization defects in iPSC-derived neurons; (2) cross-sectional study showing biomarker levels change with disease severity (Braak stage); (3) longitudinal validation showing biomarker predicts therapeutic response in a clinical trial (Phase II or higher). Biomarkers must have AUC ≥0.80 for distinguishing patients from age-matched controls. Single-marker studies are insufficient.",
  "market_price": 0.5
}